Biopeptide ELTM

THE "SPRING FRAGMENT" OF ELASTIN FOR DERMAL RESTRUCTURATION

Function and Characteristics: CTFA / INCI name:
Hydroglycolic solution of Palmitoyl - Val - Gly - Val - Ala - Glyceryl Polymethacrylate - PEG-8 - Palmitoyl
Pro - Gly titrated at 100 ppm. Oligopeptide

Cosmetic interest (properties): Specifications:

BIOPEPTIDE EL stimulates fibroblasts mobility and is Appearance : gel
particularly active on skin suppleness. Colour : practically colourless
Odour : characteristic
Applications: pH (sol. at 10%) :4-6
Firming products, eye contour products and hand care Refractive index (25°C) : 1.430 - 1.440
products. Water content (K. Fischer) : 22 - 28%
Pal - VGVAPG content (HPLC) : 100 - 140 ppm
Recommended use level: 2 to 5% Bacteria : < 100 germs/g
Yeast and moulds : < 10 germs/g

Sederma patent: FR 2 668 365 - FR 2 854 897

US 2004/0120918

CLAIM SUBSTANTIATION
IN VIVO
Measurement of cutaneous firmness:
10 volunteers / 30 days / cream containing 4% BIOPEPTIDE EL / Fermometer.

- Increase in cutaneous firmness: +24.5%

mm
0.50

0.42
FC
0.33 P E : Elasticity (elastic extension)
0.25 T : Skin tone
P : Plasticity (viscoelastic deformation)
0.17 T SF : Skin fatigue
E
0.08

0.00
1.7 3.3 5.0 6.7 8.3 10.0 sec.

- Decrease in skin plasticity: -17.6% - Decrease in skin fatigue: -19.6%

Arbitrary units Arbitrary units

2.5 2.5

2.3 2.3 -19.6%

-17.6%
2.1 2.1

1.9 1.9

1.7 1.7

1.5 1.5
D0 D30 D0 D30 D0 D30 D0 D30
Placebo Biopeptide EL 4% Placebo Biopeptide EL 4%

Sederma Tel. : +33 (0)1 34 84 10 10 E-mail: sederma@sederma.fr

29 rue du Chemin Vert
78612 Le Perray-en-Ynes Cedex France Fax : +33 (0)1 34 84 11 30 Web: www.sederma.fr